NEUROCRINE BIOSCIENCES INC Cash and Cash Equivalents
NEUROCRINE BIOSCIENCES INC (NBIX) had Cash and Cash Equivalents of $332.40 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-07-31
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $332.40M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $266.50M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $713.00M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $340.20M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $332.40M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $266.50M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $713.00M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $340.20M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $264.00M 10-Q · filed 2026-07-31 | |
| 2025-03-31 | $194.10M 10-Q · filed 2026-05-05 | |
| 2024-12-31 | $233.00M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $349.10M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $139.70M 10-Q · filed 2025-07-30 | |
| 2024-03-31 | $396.30M 10-Q · filed 2025-05-05 | |
| 2023-12-31 | $251.10M 10-K · filed 2025-02-10 | |
| 2023-09-30 | $293.70M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $160.20M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $103.80M 10-Q · filed 2024-05-01 | |
| 2022-12-31 | $262.90M 10-K · filed 2024-02-09 | |
| 2022-09-30 | $212.20M 10-Q · filed 2023-10-31 | |
| 2022-06-30 | $163.30M 10-Q · filed 2023-08-01 | |
| 2022-03-31 | $270.20M 10-Q · filed 2023-05-03 | |
| 2021-12-31 | $340.80M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $311.10M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $368.00M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $352.60M 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $187.10M 10-K · filed 2022-02-11 | |
| 2020-09-30 | $425.30M 10-Q · filed 2021-11-01 | |
| 2020-06-30 | $415.10M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $187.00M 10-Q · filed 2021-05-05 | |
| 2019-12-31 | $112.30M 10-K · filed 2021-02-05 | $112.28M 10-K · filed 2020-02-07 |
| 2019-09-30 | $166.64M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $140.99M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $72.78M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $141.71M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $195.73M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $166.42M 10-Q · filed 2018-07-31 | |
| 2018-03-31 | $175.31M 10-Q · filed 2018-04-30 | |
| 2017-12-31 | $254.71M 10-K · filed 2019-02-08 | |
| 2017-09-30 | $267.82M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $309.50M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $64.09M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $83.27M 10-K · filed 2018-02-13 | |
| 2016-09-30 | $99.76M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $86.25M 10-Q · filed 2017-08-03 | |
| 2016-03-31 | $115.30M 10-Q · filed 2017-05-09 | |
| 2015-12-31 | $74.19M 10-K · filed 2018-02-13 | |
| 2015-09-30 | $66.38M 10-Q · filed 2016-11-02 | |
| 2015-06-30 | $132.07M 10-Q · filed 2016-08-03 | |
| 2015-03-31 | $170.26M 10-Q · filed 2016-05-05 | |
| 2014-12-31 | $31.01M 10-K · filed 2018-02-13 | |
| 2014-09-30 | $29.05M 10-Q · filed 2015-10-29 | |
| 2014-06-30 | $37.45M 10-Q · filed 2015-07-29 | |
| 2014-03-31 | $105.53M 10-Q · filed 2015-04-30 | |
| 2013-12-31 | $44.79M 10-K · filed 2017-02-14 | |
| 2013-09-30 | $34.89M 10-Q · filed 2014-11-04 | |
| 2013-06-30 | $44.31M 10-Q · filed 2014-08-06 | |
| 2013-03-31 | $31.55M 10-Q · filed 2014-05-01 | |
| 2012-12-31 | $63.75M 10-K · filed 2016-02-11 | |
| 2012-09-30 | $44.49M 10-Q · filed 2013-10-29 | |
| 2012-06-30 | $42.02M 10-Q · filed 2013-07-26 | |
| 2012-03-31 | $76.94M 10-Q · filed 2013-05-02 | |
| 2011-12-31 | $50.11M 10-K · filed 2015-02-09 | |
| 2011-09-30 | $39.52M 10-Q · filed 2012-10-31 | |
| 2011-06-30 | $18.84M 10-Q · filed 2012-07-31 | |
| 2011-03-31 | $24.39M 10-Q · filed 2012-05-02 | |
| 2010-12-31 | $54.05M 10-K · filed 2014-02-11 | |
| 2010-09-30 | $77.33M 10-Q · filed 2011-10-31 | |
| 2010-06-30 | $95.12M 10-Q · filed 2011-07-29 | |
| 2009-12-31 | $37.33M 10-K · filed 2013-02-08 | |
| 2008-12-31 | $68.47M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |